Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies.
- DOI
- 10.1038/s41433-022-02092-5
- Published
- 2023 Apr
- Container
- Eye (London, England)
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1038/s41433-022-02092-5,
title = {Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies.},
author = {Lally DR and Loewenstein A and Arnold JJ and Yang YC and Gedif K and Best C and Patel H and Tadayoni R and Heier JS},
year = {2023},
journal = {Eye (London, England)},
doi = {10.1038/s41433-022-02092-5},
url = {https://doi.org/10.1038/s41433-022-02092-5}
}RIS
TY - JOUR TI - Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies. AU - Lally DR AU - Loewenstein A AU - Arnold JJ AU - Yang YC AU - Gedif K AU - Best C AU - Patel H AU - Tadayoni R AU - Heier JS PY - 2023 JO - Eye (London, England) DO - 10.1038/s41433-022-02092-5 UR - https://doi.org/10.1038/s41433-022-02092-5 ER -
APA
DR, L., A, L., JJ, A., YC, Y., K, G., C, B., H, P., R, T., & JS, H. (2023). Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies.. Eye (London, England). https://doi.org/10.1038/s41433-022-02092-5
Source records
- pubmed · retrieved 2026-09-26T13:15:16.612Z